Journal
GASTROENTEROLOGY
Volume 146, Issue 6, Pages 1554-1563Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2014.01.050
Keywords
Probiotic; Prebiotic; Fecal Transplantation; Pharmabiotic
Categories
Funding
- Science Foundation Ireland [SFI/12/RC/2273, 12/RC/2273]
- Science Foundation Ireland (SFI) [12/RC/2273] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
There is compelling rationale for manipulating the microbiota to treat inflammatory bowel diseases (IBDs). Although studies of animal models of intestinal inflammation produced promising results, trials in humans have been disappointing. In contrast to IBD, the role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been considered, but early stage results have been encouraging. As pharmaceutical companies develop fewer truly novel agents for treatment of these disorders, consumers seek safer, long-term strategies to deal with chronic symptoms. We assess the rationale for modulating the microbiota for treatment of IBD and IBS, and discuss whether current concepts are simplistic and overstated or simply under-researched. Are claims exaggerated and expectations unrealistic? Difficulties with microbiota terminology and technologies, as well as differences among patients and the heterogeneity of these diseases, pose additional challenges in developing microbiota-based therapies for IBD and IBS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available